A
Andrew H. Ko
Researcher at University of California, San Francisco
Publications - 204
Citations - 11776
Andrew H. Ko is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Pancreatic cancer & Gemcitabine. The author has an hindex of 44, co-authored 182 publications receiving 8384 citations. Previous affiliations of Andrew H. Ko include Northwestern University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Eric A. Collisson,Anguraj Sadanandam,Anguraj Sadanandam,Peter Olson,Peter Olson,William J. Gibb,William J. Gibb,Morgan L. Truitt,Shenda Gu,J. Cooc,Jennifer Weinkle,Grace E. Kim,Lakshmi Jakkula,Heidi S. Feiler,Andrew H. Ko,Adam B. Olshen,Kathleen L Danenberg,Margaret A. Tempero,Paul T. Spellman,Douglas Hanahan,Douglas Hanahan,Joe W. Gray,Joe W. Gray +22 more
TL;DR: Three PDA subtypes are defined: classical, quasimesenchymal and exocrine-like, and evidence for clinical outcome and therapeutic response differences between them is presented, and gene signatures for these subtypes that may have utility in stratifying patients for treatment are defined.
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Journal ArticleDOI
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero,Mokenge P. Malafa,Mahmoud M. Al-Hawary,Horacio J. Asbun,Andrew Bain,Stephen W. Behrman,Al B. Benson,Ellen F. Binder,Dana Backlund Cardin,Charles Cha,E. Gabriela Chiorean,Vincent Chung,Brian G. Czito,Mary Dillhoff,Efrat Dotan,Cristina R. Ferrone,Jeffrey M. Hardacre,William G. Hawkins,Joseph M. Herman,Andrew H. Ko,Srinadh Komanduri,Albert C. Koong,Noelle K. LoConte,Andrew M. Lowy,Cassadie Moravek,Eric K. Nakakura,Eileen M. O'Reilly,Jorge Obando,Sushanth Reddy,Courtney L. Scaife,Sarah P. Thayer,Colin D. Weekes,Robert A. Wolff,Brian M. Wolpin,Jennifer L. Burns,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection, as well as on management of locally advanced unresectable and metastatic disease.
Journal ArticleDOI
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J. Kelly,Jaffer A. Ajani,Jarosław Kużdżał,Thomas Zander,Eric Van Cutsem,Guillaume Piessen,Guillermo Mendez,Josephine Feliciano,Satoru Motoyama,Astrid Lièvre,Hope E. Uronis,Elena Elimova,Cecile Grootscholten,Karen Geboes,Syed Nabeel Zafar,Stephanie J Snow,Andrew H. Ko,Kynan Feeney,Michael Schenker,Piotr Kocoń,Jenny Zhang,Lili Zhu,Ming Lei,Prianka Singh,Kaoru Kondo,James M. Cleary,Markus Moehler +26 more
TL;DR: In this paper, no adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageaal...
Journal ArticleDOI
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara,Eric Van Cutsem,Yung-Jue Bang,Charles S. Fuchs,Lucjan Wyrwicz,Keun Wook Lee,Iveta Kudaba,Marcelo Garrido,Hyun Cheol Chung,Jeeyun Lee,Hugo Castro,Wasat Mansoor,Maria Ignez Braghiroli,Nina A. Karaseva,Christian Caglevic,Luis Villanueva,Eray Goekkurt,Hironaga Satake,Peter C. Enzinger,Maria Alsina,Al B. Benson,Joseph Chao,Andrew H. Ko,Zev A. Wainberg,Uma Kher,Sukrut Shah,S. Peter Kang,Josep Tabernero +27 more
TL;DR: This phase 3 randomized clinical trial found that among patients with untreated, advanced G/GEJ cancer, pembrolizumab was noninferior to chemotherapy, with fewer adverse events observed.